Live

partnership agreement

2 articles

Biogen Partners With Alloy to Accelerate Antisense Drug Development Pipeline

Benzinga

Benzinga·Apr 7·Vandana Singh

Biogen Partners With Alloy to Accelerate Antisense Drug Development Pipeline

Biogen partners with Alloy Therapeutics to advance antisense oligonucleotide therapies using the AntiClastic platform for multiple undisclosed disease indications.

SNYAPLSBIIBrare diseasesimmunology

Hims & Hers Surges 40% on Novo Nordisk Deal, But Valuation Concerns Linger

The Motley Fool

The Motley Fool·Mar 9·Geoffrey Seiler

Hims & Hers Surges 40% on Novo Nordisk Deal, But Valuation Concerns Linger

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.

NVOHIMSGLP-1 drugstelemedicine